MS drugs cut relapses but did not change relapse recovery
By MS Buddy ·
Summarized from Multiple sclerosis (Houndmills, Basingstoke, England), Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
Observational study · people with relapsing-remitting MS (flare-ups followed by periods of recovery)
Research by Marcus Koch, Gary Cutter and 9 colleagues at the University of Calgary, Rijnstate Hospital and 6 other institutions in the United States, Canada, the Netherlands and 1 other country.
Do MS treatments change relapse severity or recovery once a relapse happens?
Key Takeaway
MS treatments reduced relapses but did not change their severity or recovery time once they occurred.

What They Found
Researchers examined the first relapse after treatment started across four large trials. Long-term MS treatments reduced relapse rates compared with placebo (a treatment with no active drug) or interferon (an MS medicine). Treatment groups did not differ in how severe those relapses were. Recovery followed a similar pattern across trials, with most improvement occurring within about 90–120 days. Steroids (medicines used to treat relapses) were not linked to recovery time.
Who Should Care and Why
This study examined people with relapsing-remitting MS (MS with flare-ups followed by periods of recovery). It focused on the first relapse after treatment began. The findings separate preventing relapses from changing what happens during a relapse. Treatments reduced how often relapses happened, without changing their severity or recovery time. The findings concern relapsing-remitting MS, rather than progressive forms of MS.
Important Considerations
This was an analysis of four large treatment trials; the abstract does not report the number of participants. The analysis focused on the first relapse after treatment started, not every later relapse. These findings cannot tell you how severe an individual relapse will be or how long recovery will take.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Multiple sclerosis (Houndmills, Basingstoke, England) by et al.. Reproduced from the PubMed record.
Relapses are the defining clinical feature of relapsing-remitting multiple sclerosis, but it remains uncertain whether disease-modifying treatments influence relapse severity or recovery once a relapse occurs. We investigated whether disease-modifying treatment exposure affects the severity of and recovery from clinical relapses across four pivotal phase 3 relapsing-remitting multiple sclerosis trials. We used logistic regression models to assess predictors of severe first relapse (Expanded Disability Status Scale worsening > 1.0 point), and Cox proportional hazards models to evaluate factors associated with time to recovery. Predictors included age, sex, disease duration, baseline Expanded Disability Status Scale, T2 lesion volume, contrast-enhancing lesions, relapse severity, corticosteroid treatment and treatment arm. Across all trials, disease-modifying treatments significantly reduced the annualized relapse rate (p < 0.0001) compared to placebo or interferon as an active comparator, but were not associated with relapse severity or recovery time. Relapse recovery followed a similar two-phase course in all trials, with most recovery occurring within 90-120 days. Treatment arm and corticosteroid use were not significantly associated with the time to recovery in any dataset. While disease-modifying treatments reduce relapse frequency, they did not modify relapse severity or recovery once a relapse occurred. These findings suggest that disease-modifying treatments primarily prevent inflammatory events rather than alter their clinical evolution.
Categories
Explore more research
Related MS research

11/19/2026
A review of one MS stem cell transplant program found most procedures avoided hospital admission. Be
Read More
11/20/2026
A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac
Read More
11/19/2026
A review finds lasting control of disease activity after stem cell transplants in selected people wi
Read More
11/14/2026
In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.
Read More
11/15/2026
A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older
Read More
11/13/2026
From 2013 to 2024, more people with MS in Poland received treatment and started sooner. Stronger dru
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
